Yong-kek Pang

Kuala Lumpur, MY 
Kuala Lumpur, MY 

Overview

Yong-kek Pang practices practicing medicine in Kuala Lumpur, Malaysia.

Their clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Bronchitis, Lung Cancer, and EGFR Positive Lung Cancer.

They are actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Locations

Kuala Lumpur, Malaysia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
Enrollment Status: Completed
Publish Date: March 23, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

23 Total Publications

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.
Journal: Cancer discovery
Published: July 09, 2025

Frequently Asked Questions about Yong-kek Pang

Is Yong-kek Pang a top-rated expert for Chronic Obstructive Pulmonary Disease (COPD)?

MediFind is an objective health platform that identifies experts based on real-world data. Yong-kek Pang is classified as an Experienced expert for Chronic Obstructive Pulmonary Disease (COPD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yong-kek Pang participate in research or clinical trials?

Yes. Yong-kek Pang has published 23 articles and abstracts on conditions like Chronic Obstructive Pulmonary Disease (COPD). You can view a list of Yong-kek Pang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pang's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile